L‐type amino‐acid transporter 1 as a novel biomarker for high‐grade malignancy in prostate cancer
- 15 December 2008
- journal article
- Published by Wiley in Pathology International
- Vol. 59 (1), 7-18
- https://doi.org/10.1111/j.1440-1827.2008.02319.x
Abstract
To find reliable biomarkers for high-grade malignancy, the relationship between immunohistochemical L-type amino-acid transporter 1 (LAT1) expression of biopsy samples, determined with the newly developed monoclonal antibody against human LAT1, and prognosis of patients with prostate cancer, was investigated. The intensity and score of immunohistochemical LAT1 expression of first biopsy samples were assessed using the modified Sinicrope et al. method and were found to be correlated with poor survival for the study group of 114 surgically treated patients as a whole (P = 0.0002 and 0.0270, respectively). LAT1 intensity further had a significant relationship (P = 0.0057) with prognosis in pathological T3 + T4 groups. Multivariate analysis indicated that the LAT1 intensity and score were more reliable prognostic markers, compared with the Gleason score and the Ki-67 labeling index. A relationship of the LAT1 intensity and score with prognosis could also be confirmed in 63 patients with inoperable cancer (P = 0.0070 and <0.0001, respectively). Similarly, significant differences in prognosis were confirmed in clinical T3 + T4 groups (P = 0.0091 and 0.0244, respectively). Moreover, the combination of LAT1 expression and Gleason score was found to have a more reliable correlation with prognosis. Thus, elevated LAT1 expression in prostate cancers is a novel independent biomarker of high-grade malignancy, which can be utilized together with the Gleason score, which is mainly dependent on cellular and structural atypia, to assess prognosis.Keywords
This publication has 31 references indexed in Scilit:
- Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I–III nonsmall cell lung cancerBritish Journal of Cancer, 2008
- Predictive models and prostate cancerNature Reviews Endocrinology, 2008
- The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologically‐based screening strategyInternational Journal of Cancer, 2007
- High throughput production of mouse monoclonal antibodies using antigen microarraysProteomics, 2005
- Amino acid transporters ASCT2 and LAT1 in cancer: Partners in crime?Seminars in Cancer Biology, 2005
- Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinomaJournal of Surgical Oncology, 2005
- 12-YEAR OUTCOMES FOLLOWING PERMANENT PROSTATE BRACHYTHERAPY IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCERJournal of Urology, 2005
- Apoptosis Regulation Differs Between Ulcerative Colitis–Associated and Sporadic Colonic TumorsAmerican Journal of Clinical Pathology, 2003
- Molecular events involved in up-regulating human Na+-independent neutral amino acid transporter LAT1 during T-cell activationBiochemical Journal, 2001
- cDNA Sequencing and Analysis of POV1 (PB39): A Novel Gene Up-regulated in Prostate CancerGenomics, 1998